3. World Health Organization HIV/AIDS Programme, UNAIDS, UNICEF. Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization; 2010.
4. UNAIDS. AIDS epidemic update : November 2009. Geneva: UNAIDS; 2009.
5. Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS. 2007;21:1333–1340. [PubMed] 6. Hogan DR, Baltussen R, Hayashi C, Lauer JA, Salomon JA. Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries. BMJ. 2005;331:1431–1437. [PMC free article] [PubMed] 7. Stover J, Korenromp EL, Blakley M, Komatsu R, Viisainen K, et al. Long-term costs and health impact of continued global fund support for antiretroviral therapy. PLoS One. 2011;6:e21048. [PMC free article] [PubMed] 8. Sabot O, Cohen J, Hsiang M, Kahn J, Basu S, et al. Costs and financial feasibility of malaria elimination. Lancet. 2010;376:1604–1615. [PMC free article] [PubMed] 9. Murray C, Evans DB, Acharya A, Baltussen R. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Economics. 2000;9:235–251. [PubMed] 10. Fox MP, Rosen S, MacLeod WB, Wasunna M, Bii M, et al. The impact of HIV/AIDS on labour productivity in Kenya. Trop Med Int Health. 2004;9:318–324. [PubMed] 11. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, et al. Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health. 2009;9:240. [PMC free article] [PubMed] 12. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, et al. Early effects of antiretroviral therapy on work performance: preliminary results from a cohort study of Kenyan agricultural workers. AIDS. 2008;22:421–425. [PubMed]
13. The Global Fund to Fight AIDS Tuberculosis and Malaria. Financial and health impacts of continued support to the three diseases: long-term estimates. Geneva: The Global Fund to Fight AIDS Tuberculosis and Malaria; 2010.
14. Stover J, Johnson P, Zaba B, Zwahlen M, Dabis F, et al. The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect. 2008;84(Suppl 1):i24–i30. [PMC free article] [PubMed] 15. Mahy M, Lewden C, Brinkhof MW, Dabis F, Tassie JM, et al. Derivation of parameters used in Spectrum for eligibility for antiretroviral therapy and survival on antiretroviral therapy. Sexually transmitted infections. 2010;86(Suppl 2):ii28–34. [PMC free article] [PubMed] 16. The Global Fund to Fight AIDS Tuberculosis and Malaria. Price and Quality Reporting system. 2010. [PubMed]
18. The Global Fund to Fight AIDS Tuberculosis and Malaria. The Global Fund Results report 2010: innovation and impact. Geneva: 2010.
19. Adam T, Evans DB, Murray CJ. Econometric estimation of country-specific hospital costs: WHO-CHOICE. Cost Eff Resour Alloc. 2003;1:3. [PMC free article] [PubMed] 20. Renaud-Thery F, Avila-Figueroa C, Stover J, Thierry S, Vitoria M, et al. Utilization patterns and projected demand of antiretroviral drugs in low- and middle-income countries. AIDS research and treatment. 2011;2011:749041. [PMC free article] [PubMed]
21. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update: November 2009. Geneva: UNAIDS; 2009.
22. Haacker M. HIV/AIDS: The Impact on the Social Fabric and the Economy. In: Haacker M, editor. The Macroeconomics of HIV/AIDS. Geneva: International Monetary Fund; 2004.
23. Booysen FlR, Arntz T. The methodology of HIV/AIDS impact studies: a review of current practices. Social Science & Medicine. 2003;56:2391–2405. [PubMed] 24. Wandel S, Egger M, Rangsin R. Duration from seroconversion to eligibility for antiretroviral therapy and from ART eligibility to death in adult HIV-infected patients from low and middle-income countries: collaborative analysis of prospective studies. Sex Transm Infect. 2008;84(Suppl 1):i31–i36. [PMC free article] [PubMed] 25. Marston M, Todd J, Glynn JR, Nelson KE, Rangsin R, et al. Estimating ‘net’ HIV-related mortality and the importance of background mortality rates. AIDS. 2007;21(Suppl 6):S65–71. [PubMed] 26. Todd J, Glynn JR, Marston M, Lutalo T, Biraro S, et al. Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy. AIDS. 2007;21(Suppl 6):S55–63. [PubMed]
27. Yamano T, Jayne T. Measuring the Impacts of Working-Age Adult Mortality on Small-Scale Farm Households in Kenya. World Development. 2004;32:91–119.
28. World Health Organization HIV/AIDS Programme. Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. Geneva: 2009.
29. King JT, Jr, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med Decis Making. 2003;23:9–20. [PubMed] 30. Fox MP, McCoy K, Larson BA, Rosen S, Bii M, et al. Improvements in physical wellbeing over the first two years on antiretroviral therapy in western Kenya. AIDS Care. 2010;22:137–145. [PMC free article] [PubMed] 31. Beard J, Feeley F, Rosen S. Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care. 2009;21:1343–1356. [PubMed] 32. Morineau G, Vun MC, Barennes H, Wolf RC, Song N, et al. Survival and quality of life among HIV-positive people on antiretroviral therapy in Cambodia. AIDS Patient Care STDS. 2009;23:669–677. [PubMed] 33. Bussmann H, Wester CW, Ndwapi N, Grundmann N, Gaolathe T, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. AIDS. 2008;22:2303–2311. [PMC free article] [PubMed]
34. Thirumurthy H, Saravanan R, Srinivas G, Jafri A, Sreevidya J, et al. The impact of antiretroviral therapy on socioeconoic outcomes of HIV-infected patients in Tamil Nadu family care continuum program, India. 2008. XVII International AIDS Conference. Mexico City, Mexico.
35. Habyarimana J, Mbakile B, Pop-Eleches C. HIV/AIDS, ARV Treatment and Worker Absenteeism: Evidence from a Large African Firm. 2007.
36. Goldstein MPG-Z, J, Thirumurthy H. The household impacts of treating HIV/AIDS in Developing Countries. In: Yifu Lin J, Pleskovic B, editors. Annual World Bank Conference on Development Economics Global: People, Politics, and Globalization. Washington DC: World Bank; 2009.
37. Thirumurthy H, J G-Z, M G. The economic impact of AIDS treatment: labor supply in Western Kenya. Journal of Human Resources. 2008;43:511–552. [PMC free article] [PubMed]
38. Linnemayr S, Lawson BS, Glick P, Wagner G. Economic Status and Coping Mechanisms of Individuals Seeking HIV Care in Uganda. Journal of African Economies. 2011;20:505–529.
39. Thirumurthy H, Jafri A, Srinivas G, Arumugam V, Saravanan RM, et al. Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. AIDS. 2011;25:239–246. [PubMed]
40. Sgombich X, Bahamondes L, Cid C. Quality of life in work, absenteeism, and HAART in workers living with HIV. 2006. XVI International AIDS Conference. Toronto, Canada.
41. Eholie S, Nolan M. Antiretroviral treatment can be cost-savings for industry and life-saving for workers: a case study from Cote d'Ivoire's private sector. In: Moatti J, Barnett T, Coriat B, Souteyrand Y, Dumoulin J, et al., editors. Economics of AIDS and access to HIV/AIDS care in developing countries: issues and challenges. Paris, France: Agence Nationale de Recherches sur le Sida; 2003. pp. 329–346.
42. E B, van Zyl A, Myer-Rath G, Letlape O, Ndibongo B, et al. A cost-benefit analysis of employer provided highly active antiretroviral therapy to HIV positive employees of a large South African mining company. International Health Economics Association Beijing; 2009.
43. Rosen S, Ketlhapile M, Sanne I, Desilva MB. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008;22(Suppl 1):S131–139. [PubMed]
44. Coetzee C. The impact of highly active antiretroviral treatment (HAART) on employment in Khayelitsha. South African Journal of Economics. 2008;76:S76–S85.
45. Muirhead D, Kumaranayake L, Hongoro C, Charalambous S, Grant A, et al. Health care costs, savings, and productivity benefits resulting from a large employer sponsored ART program in South Africa. 2006. XVI International AIDS Conference. Toronto, Caanada.
46. International Labour Organization. 2009. LABORSTA Labour Statistics Database 2 Feb 2010 ed.
47. World Bank. World Development Indicators Online 8 Oct 2009 ed. World Bank; 2009.
48. Barnighausen T, Hosegood V, Timaeus IM, Newell ML. The socioeconomic determinants of HIV incidence: evidence from a longitudinal, population-based study in rural South Africa. AIDS. 2007;21(Suppl 7):S29–38. [PMC free article] [PubMed] 49. Gillespie S, Kadiyala S, Greener R. Is poverty or wealth driving HIV transmission? AIDS. 2007;21(Suppl 7):S5–S16. [PubMed] 50. Tsai AC, Chopra M, Pronyk PM, Martinson NA. Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care. 2009;21:59–63. [PubMed]
51. Haacker M. HIV/AIDS, Economic Growth, Inequality. In: Sahn D, editor. The Socioeconomic Dimensions of HIV/AIDS in Africa. Ithaca: Cornell University Press; 2010.
52. Mahal A, Canning D, Odumosu K, Okonkwo P. Assessing the economic impact of HIV/AIDS on Nigerian households: a propensity score matching approach. AIDS. 2008;22(Suppl 1):S95–101. [PubMed]
53. Beegle K, DeWeerdt J, Dercon S. Orphanhood, and the long-run impact on children. Center for the studies of African economics; 2007.
54. UNAIDS, UNICEF, USAID. Children on the Brink: A Joint Report of New Orphan Estimates and Framework for Action. 2004.
55. Stover J, Bollinger L, Walker N, Monasch R. Resource needs to support orphans and vulnerable children in sub-Saharan Africa. Health Policy Plan. 2007;22:21–27. [PubMed] 56. Foster G, Williamson J. A review of current literature on the impact of HIV/AIDS on children in sub-Saharan Africa. AIDS. 2000;14(Suppl 3):S275–284. [PubMed]
57. Bollinger L, Stover J. Finanacial resources required to achieve universal access to HIV prevention, treatment, care and support: methodology for care and treatment- methodological annex III 2007
58. Tan-Torres Edejer T. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003.
59. Gold MR, Siegel JE, Russell LB, Weinstein MC, editors. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
60. Lu C, Schneider MT, Gubbins P, Leach-Kemon K, Jamison D, et al. Public financing of health in developing countries: a cross-national systematic analysis. Lancet. 2010;375:1375–1387. [PubMed] 61. Izazola-Licea JA, Wiegelmann J, Aran C, Guthrie T, de Lay P, et al. Financing the response to HIV in low-income and middle-income countries. J Acquir Immune Defic Syndr. 2009;52:S119–S126. [PubMed] 62. Cuddington JT, Hancock JD. The macroeconomic impact of AIDS in Malawi: a dualistic, labour surplus economy. J Afr Econ. 1995;4:1–28. [PubMed] 63. Thurlow J, Gow J, George G. HIV/AIDS, growth and poverty in KwaZulu-Natal and South Africa: an integrated survey, demographic and economy-wide analysis. J Int AIDS Soc. 2009;12:18. [PMC free article] [PubMed] 64. Ventelou B, Moatti JP, Videau Y, Kazatchkine M. ‘Time is costly’: modelling the macroeconomic impact of scaling-up antiretroviral treatment in sub-Saharan Africa. AIDS. 2008;22:107–113. [PubMed]
65. Jeffries K, Siphanmbe H, Kinghorn A. The economic impact of HIV/AIDS in Botswana. Econsult Pty Ltd; 2006.
66. Bell C, Devarajan S, Gersbach H. Thinking about the long-run economic costs of AIDS. In: Haacker M, editor. The Macroeconomics of HIV/AIDS. Geneva: International Monetary Fund; 2004.
67. Becker GS, Philipson TJ, Soares RR. The quantity and quality of life and the evolution of world inequality. Cambridge: National Bureau of Economic Research. 2003. Working Paper 9765 Working Paper 9765.
69. Jamison DT, Sachs JD, Wang J. The Effect of the AIDS Epidemic on Economic Welfare in Sub-Saharan Africa. Commission on Macroeconomics and Health; 2001.
70. Viscusi K, Aldy J. The value of a statistical life: A critical review of market estimates from around the world. Journal of Risk and Uncertainty. 2003;27:5–76.